NCT06462547View on ClinicalTrials.gov

ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

November 30, 2030

Study Completion Date

December 31, 2030

Conditions
Gene MutationsPseudoxanthoma ElasticumArterial CalcificationEctonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic Rickets Type 2
Interventions
DRUG

INZ-701

INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).

Trial Locations (5)

55905

RECRUITING

Mayo Clinic, Rochester

07724

RECRUITING

Clinilabs Drug Development Corporation, Eatontown

Unknown

RECRUITING

Necker-Enfants Malades Hospital, Paris

RECRUITING

Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg

RECRUITING

VCTC, Oxford

Sponsors

Lead Sponsor

Inozyme Pharma
All Listed Sponsors
lead

Inozyme Pharma

INDUSTRY

NCT06462547 - ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency | Biotech Hunter | Biotech Hunter